All Brands Owned by Sanofi

Sanofi Genzyme's oral disease-modifying therapy (teriflunomide) for relapsing forms of multiple sclerosis, FDA approved September 12, 2012, that works by inhibiting dihydroorotate dehydrogenase (DHODH) to selectively reduce proliferating lymphocytes driving MS inflammation.

Prescription human papillomavirus vaccine for preventing cervical cancer and other HPV-related diseases, manufactured and marketed by Sanofi.

Blockbuster biologic medication (dupilumab) co-developed by Sanofi and Regeneron Pharmaceuticals, FDA approved March 28, 2017, with more than 8 approved indications and $14.9 billion in global sales in 2024.

Sanofi's long-acting insulin glargine for type 1 and type 2 diabetes, FDA approved April 2000, that reached peak global sales of $6.4 billion in 2015 before biosimilar competition from Basaglar, Semglee, and Rezvoglar significantly eroded its market share and revenues.

Sanofi Genzyme's high-efficacy anti-CD52 monoclonal antibody (alemtuzumab) for active relapsing-remitting multiple sclerosis, FDA approved November 14, 2014, reserved for patients with inadequate response to two or more disease-modifying therapies due to its serious risk profile and REMS program.

Prescription combination vaccine for preventing diphtheria, tetanus, pertussis, polio, and Haemophilus influenzae type b, manufactured and marketed by Sanofi.

Clopidogrel antiplatelet medication co-developed by Sanofi and Bristol-Myers Squibb, FDA approved in 1997, that became the world's second best-selling drug before its patent expired in May 2012.

Sanofi's taxane chemotherapy (docetaxel), FDA approved in 1996 for breast cancer and later for lung, prostate, gastric, and head and neck cancers, that generated $1.4 billion annually by 2004 before generic competition and became subject to major litigation over undisclosed risk of permanent hair loss.